← Leaderboards
Hyon K Choi
Brigham And Women'S Hospital
$12,976,398
Attributed
$17,346,475
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,346,475 · 11
By mechanism
R01$7,127,747 · 2
U01$5,795,791 · 1
P50$1,536,186 · 1
R21$1,179,142 · 3
RC1$999,956 · 1
R34$457,435 · 1
Top collaborators
- Michael J Barry5 shared
- Daniel Hal Solomon5 shared
- Ronald Melles2 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Gary C. Curhan$15,291,553
- Rong Tian$29,765,984
- Daniel Hal Solomon$26,002,677
- Seoyoung Catherine Kim$5,029,016
- John Travis Hinson$8,448,361
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortAffectGoutPainUrateRheumatologyHyperuricemiaSerumRisk FactorsInflammatory ArthritisAmericanBaseCessation Of LifePharmaceutical PreparationsAdultPrematureLife StyleCaringFlarePrevalenceDietInflammationProspectiveResearch Design
Grant awards (33)
Treat-to-Target Serum Urate versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial (TRUST)$1,812,686
U01 · FY2025 · AR · contact PI
NOVEL METABOLITE AND MICROBIOTA PATHWAYS FOR HYPERURICEMIA AND GOUT$639,196
R01 · FY2025 · AR · contact PI
SGLT2i As Novel Gout Care (SAVE-Care): A Randomized Controlled Trial$228,218
R61 · FY2025 · AR · contact PI
Treat-to-Target Serum Urate versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial (TRUST)$1,937,050
U01 · FY2024 · AR · contact PI
NOVEL METABOLITE AND MICROBIOTA PATHWAYS FOR HYPERURICEMIA AND GOUT$723,144
R01 · FY2024 · AR · contact PI
Treat-to-Target Serum Urate versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial (TRUST)$2,046,055
U01 · FY2023 · AR · contact PI
NOVEL METABOLITE AND MICROBIOTA PATHWAYS FOR HYPERURICEMIA AND GOUT$782,632
R01 · FY2023 · AR · contact PI
NOVEL METABOLITE AND MICROBIOTA PATHWAYS FOR HYPERURICEMIA AND GOUT$779,329
R01 · FY2022 · AR · contact PI
Project 2: Novel Risk Factors and Precision Medicine for Gout Flares$315,684
P50 · FY2021 · AR · contact PI
Planning for a Trial of Comparative Effectiveness of Gout Management Strategies$217,868
R34 · FY2021 · AR · contact PI
The Risk and Risk Factors of Incident Hydroxychloroquine Retinopathy Among Long-Term Users$136,012
R21 · FY2021 · AR · contact PI
Project 2: Novel Risk Factors and Precision Medicine for Gout Flares$254,064
P50 · FY2020 · AR · contact PI
Planning for a Trial of Comparative Effectiveness of Gout Management Strategies$239,567
R34 · FY2020 · AR · contact PI
The Risk and Risk Factors of Incident Hydroxychloroquine Retinopathy Among Long-Term Users$266,507
R21 · FY2019 · AR · contact PI
Project 2: Novel Risk Factors and Precision Medicine for Gout Flares$262,546
P50 · FY2019 · AR · contact PI
Project 2: Novel Risk Factors and Precision Medicine for Gout Flares$254,980
P50 · FY2018 · AR · contact PI
Project 2: Novel Risk Factors and Precision Medicine for Gout Flares$448,912
P50 · FY2017 · AR · contact PI
Taskforce for the Generation of Evidence to Resolve the Gout Care Guideline Conflict (TOGETHER) Conference$22,000
R13 · FY2017 · AR · contact PI
Impact of Cardiovascular and Weight Loss diets on Uric Acid and Gout Risk$163,972
R01 · FY2016 · AR · contact PI
Methodologic Remedies for the Risk Factor Paradox in Osteoarthritis Progression$102,006
R21 · FY2016 · AR · contact PI
Impact of Cardiovascular and Weight Loss diets on Uric Acid and Gout Risk$358,507
R01 · FY2015 · AR · contact PI
Methodologic Remedies for the Risk Factor Paradox in Osteoarthritis Progression$251,117
R21 · FY2015 · AR · contact PI
Impact of Cardiovascular and Weight Loss diets on Uric Acid and Gout Risk$390,828
R01 · FY2014 · AR · contact PI
Impact of Cardiovascular and Weight Loss diets on Uric Acid and Gout Risk$379,402
R01 · FY2013 · AR · contact PI
Genetics of Gout$682,772
R01 · FY2011 · AR · contact PI
Genetics of Gout$729,655
R01 · FY2010 · AR · contact PI
Clinical and Cost-effectiveness of biologics in Rheumatoid Arthritis$500,000
RC1 · FY2010 · AR · contact PI
Genetics of Gout$753,036
R01 · FY2009 · AR · contact PI
Clinical and Cost-effectiveness of biologics in Rheumatoid Arthritis$499,956
RC1 · FY2009 · AR · contact PI
Risk Factors for Gout Among Women$192,500
R21 · FY2009 · AR · contact PI
Genetics of Gout$1
R01 · FY2009 · AR · contact PI
Genetics of Gout$745,273
R01 · FY2008 · AR · contact PI
Risk Factors for Gout Among Women$231,000
R21 · FY2008 · AR · contact PI